Clinical Trial Update: Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020 [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of AVI-4020 in cerebrospinal fluid after a single dose, completed for the West Nile virus indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• West Nile Virus Infection

Drugs mentioned

• AVI-4020 (AVI-4020)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: West Nile Virus | Phase 1 | Status: COMPLETED